Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Biogen | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Biogen

TECFIDERA revenues up 7% in the quarter

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Biogen

2Q Revenues: $2.6 billion (+7%)

2Q Earnings: $927 million (+30%)

FY Revenues: $5.1 billion (+13%)

FY Earnings: $1.7 billion (+45%)

Comments: Multiple sclerosis product sales were $2.1 billion compared to $2.0 billion in the same quarter last year. TECFIDERA revenues in the quarter increased 7% to $883 million. Interferon revenues, including AVONEX and PLEGRIDY, were $690 million, down 9%. TYSABRI revenues were $463 million, down 13%. Revenues relating to RITUXAN and GAZYVA from Biogen’s unconsolidated joint business arrangement were $338 million, up 12%. ELOCTATE revenues were $74 million and ALPROLIX revenues were $54 million in the quarter.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters